A pharmacogenomic study on cisplatin-induced nausea and vomiting.(TRIPLE Pharmacogenomics Study)

A pharmacogenomic study on cisplatin-induced nausea and vomiting.(TRIPLE Pharmacogenomics Study) - TRIPLE Pharmacogenomics Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009335

Enrollment

200

Registered

2012-11-19

Start date

2012-11-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor (lung cancer,gastric cancer,esophagus cancer,cervical cancer,endometrial cancer,head and neck cancer,etc)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who enrolled onto TRIPLE study. 2. All participants must be able to provide written informed concent prior to entry.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Association between pharmacogenetic biomarkers and cisplatin induced nausea and vomiting.	—

Countries

Japan

Contacts

Public ContactDaiki Tsuji

Univercity of Shizuoka School of Pharmaceutical Science

d-tsuji@u-shizuoka-ken.ac.jp054-264-5674

Outcome results